IITRI Scientists Post Findings on Soy Isoflavone Mixture, Targretin, Dietary Restriction, Zebularine and Vitamin D3

IITRI scientists presented four abstracts at the 45th annual meeting of the Society of Toxicology March 5-9, 2006, in San Diego, CA.

• Chronic Toxicity Evaluation of a Characterized Soy Isoflavone Mixture in Dogs. Authors are J. Brooks Harder, William D. Johnson, and David L. McCormick of IITRI; Robert L. Morrissey of Pathology Associates; and Izet M. Kapetanovic and James A. Crowell of the National Cancer Institute.


• Chronic Toxicity Evaluation of a Characterized Soy Isoflavone Mixture in Rats. Authors are William D. Johnson, Thomas L. Horn, and David L. McCormick of IITRI; Robert L. Morrissey of Pathology Associates; and Izet M. Kapetanovic and James A. Crowell of the National Cancer Institute.


• Subchronic Toxicity Evaluation of Tamoxifen + Targretin in Female Rats. Authors are Thomas L. Horn, William D. Johnson, and David L. McCormick of IITRI; Carol J. Detrisac of Pathology Associates; and Izet M. Kapetanovic and James A. Crowell of the National Cancer Institute.


• Differential Hepatic Expression of Genes Regulating Drug and Lipid Metabolism in Rats Exposed to Targretin. Authors are Jennifer Naylor, Karen E. O. Torres, Thomas L. Horn, and David L. McCormick of IITRI; and Izet M. Kapetanovic, Ronald A. Lubet and James A. Crowell of the National Cancer Institute.

IITRI scientists presented three abstracts at the 97th annual meeting of the American Association for Cancer Research April 1-5, 2006, in Washington, D.C.

• Chronic Dietary Restriction Does Not Inhibit Androgen-Dependent Prostate Carcinogenesis in the Wistar-Unilever Rat Model. Authors are David L. McCormick and William D. Johnson of IITRI; Maarten C. Bosland of New York University School of Medicine; and Ronald A. Lubet and Vernon. E. Steele of the National Cancer Institute.


• A Pharmacokinetic/Pharmacodynamic Approach to Evaluating the Safety of Zebularine in Non-Human Primates. Authors are William D. Johnson, J. Brooks Harder, and David L. McCormick of IITRI; Carol J. Detrisac of Pathology Associates; and Elizabeth M. Glaze and Joseph E. Tomaszewski of the National Cancer Institute.


• Chemopreventive Efficacy and Growth Inhibition of Breast Cancer Cells by 25-Hydroxyvitamin D3 May Not Require Conversion to 1,25-Dihydroxy Vitamin D3. Authors are Xinjian Peng, Michael Hawthorne, and Rajendra G. Mehta of IITRI.

IITRI scientists presented two posters at the 13th Vitamin D Workshop April 7-12, 2006, in Victoria, British Columbia, Canada:

• Prohibitin Is Involved in the Antiproliferative Action of Vitamin D in Breast Cancer Cells. Authors are Xinjian Peng and Rajendra G. Mehta of IITRI, and Rajeshwari R. Mehta of the University of Illinois at Chicago.


• Human Colon Cancer Cells Express Cyp27b1 and Their Proliferation Is Inhibited by 25-Hydroxyvitamin D3. Authors are Genoveva Murillo, Xinjian Peng, and Rajendra G. Mehta of IITRI.; and Richard V. Benya of the University of Illinois at Chicago.